Tagged Articles

type 2 80 articles

Paula Deen promotes diabetes drug with possible thyroid cancer risk

Paula Deen, the celebrity chef who has built a career on fried and fattening Southern foods, announced this week on NBC’s Today show that she has been living with type 2 diabetes for three years, and that she has come public with her diagnosis to help promote a new diabetes drug. Deen, who will turn 65 on Thursday, is now a spokesperson for Novo Nordisk, and is promoting the drug company’s online program, Diabetes in a New Light. She admits she is taking the company’s once-daily noninsulin injection, Victoza. Considered a first line defense for people with type 2 diabetes, ... Read More

Non-invasive diabetes, weight loss device mimics gastric bypass

GI Dynamics has created an innovative, non-surgical device to treat type 2 diabetes and/or obesity that is showing positive results in studies worldwide. The EndoBarrier Gastrointestinal Liner simulates the effect of gastric bypass without invasive surgery. The device looks like a long, clear plastic stocking, and is threaded through the patient’s mouth and stomach, down the intestine, where it lines the upper part of the intestines – the same area that is bypassed in traditional gastric bypass surgery. Food is able to slip through the device, but digestive enzymes are trapped on its other side. The enzymes meet up with ... Read More

Study: thousands of type 2 diabetics may not have the disease at all

People who are being medicated for type 2 diabetes but experience no symptoms may not have the disease at all, says Dr. Patrick Sharp, secretary of the Association of British Clinical Diabetologists. A new study conducted by the Royal College of General Practitioners and NHS Diabetes reveals that two percent of those diagnosed with type 2 diabetes in the United Kingdom – or about 50,000 people – didn’t have the condition at all. “We know people without symptoms are being diagnosed on the basis of just one test,” Dr. Sharp told Lifestyle UK. “We could be medicating people who never ... Read More

Class action lawsuit filed in Canada against Actos maker

A class action lawsuit has been filed in Canada against Takeda Pharmaceutical Company, the manufacturer and distributor of Actos (pioglitazone hydrochloride), and Eli Lilly, the drug company’s former distributor, alleging the drug companies failed to disclose that taking the type 2 diabetes drug for longer than a year increased the chances of developing bladder cancer. The lawsuit was filed with the Ontario Superior Court of Justice. The lead plaintiff in the case is a Toronto woman who was prescribed Actos in 2002. She died two years after being diagnosed with bladder cancer. Her daughter alleges that her mother would never ... Read More

TZD category of diabetes drugs should be taken with caution

People who suffer from type 2diabetes should be wary of a category of medicines used to treat the disorder, as the drugs have been linked to serious complications, according to a report in the Corpus Christi Caller-Times. This category of diabetes drugs is known as TZDs, which are designed to help the liver and fat cells respond appropriately to insulin. This process results in decreased levels of fat and cholesterol in the blood while preserving the insulin-producing cells in the pancreas, known as beta cells. While this process helps to keep insulin levels in check for diabetics, it may be ... Read More

Study links another diabetes drug to cancer

Diabetics who use the world’s top-selling insulin drug Lantus may have more than double the risk of developing cancer, whereas those using the generic drug metformin had an 8 percent lower risk of developing cancer, according to a new study. The research, presented at the San Antonio Breast Cancer Symposium, was based on medical record of 23,266 patients in southern Sweden. The study did not identify which types of cancer were most common among Lantus users, but it did suggest that the diabetes drug could possibly play a role in the development of cancer and that the type of drug ... Read More

Night shift employees at greater risk for diabetes

People who work the night shift are far more likely to suffer from diabetes, according to a new study by the Harvard School of Public Health. They also are more apt to suffer from sleep disorders, obesity, and heart disease. The study involved more than 175,000 nurses working either the morning shift or the night shift. Those who worked the night shift there or four times a month were more likely to develop type 2 diabetes compared with nurses who didn’t work the night shift. The risk increased by as much as 60 percent with nurses who worked the night ... Read More

Prediabetes is a diagnosis to take seriously

More than 90 percent of an estimated 60 million Americans are on the verge of getting type 2 diabetes but are completely unaware that they are at risk, according to HealthWomen.org. Many of these people have no symptoms, and many who learn they have the condition known as prediabetes think it’s no big deal. But a diagnosis of prediabetes is nothing to take lightly, says Ann Albright, PhD, RD, director of the Division of Diabetes Translation at the Centers for Disease Control and Prevention. The good news, she says, “is there is something you can do about it.” Prediabetes, as ... Read More

FDA considers type 2 diabetes treatments for children, adolescents

Type 2 diabetes used to be a disease that affected mostly adults who were overweight and over 40. But as obesity has grown among children and teenagers, the condition is increasing among youths between the ages of 10 and 19. An estimated 1 in 6 children and teens is obese, according to the Centers for Disease Control and Prevention. While losing weight through diet and exercise is the first line of treatment for children with type 2 diabetes, many kids may need medication to control their blood sugar. Only one drug is approved by the Food and Drug Administration (FDA) ... Read More

European drug authorities push for stronger warnings on Actos

European drug authorities have confirmed an earlier decision not to ban the type 2 diabetes treatment Actos (pioglitazone) even though studies have linked the drug to bladder cancer. The decision goes against the actions of drug regulators in France and Germany, both of whom had advised doctors to stop prescribing the drug based on the same data. The European Medicines Agency’s decision is based on a recommendation by its Committee for Medicinal Products for Human Use (CHMP), that said in lieu of taking the drug off the market, the drug’s label should include a warning of the associated cancer risk. ... Read More